These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 36382580)
1. Methyltransferase-like 3 promotes cervical cancer metastasis by enhancing cathepsin L mRNA stability in an N6-methyladenosine-dependent manner. Liu P; Ju M; Zheng X; Jiang Y; Yu X; Pan B; Luo R; Jia W; Zheng M Cancer Sci; 2023 Mar; 114(3):837-854. PubMed ID: 36382580 [TBL] [Abstract][Full Text] [Related]
2. The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis. Zhang HM; Qi FF; Wang J; Duan YY; Zhao LL; Wang YD; Zhang TC; Liao XH Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742899 [TBL] [Abstract][Full Text] [Related]
3. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer. Yue B; Song C; Yang L; Cui R; Cheng X; Zhang Z; Zhao G Mol Cancer; 2019 Oct; 18(1):142. PubMed ID: 31607270 [TBL] [Abstract][Full Text] [Related]
4. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Chen M; Wei L; Law CT; Tsang FH; Shen J; Cheng CL; Tsang LH; Ho DW; Chiu DK; Lee JM; Wong CC; Ng IO; Wong CM Hepatology; 2018 Jun; 67(6):2254-2270. PubMed ID: 29171881 [TBL] [Abstract][Full Text] [Related]
5. Genetic and pharmacological inhibition of METTL3 alleviates renal fibrosis by reducing EVL m6A modification through an IGF2BP2-dependent mechanism. Ni WJ; Zhou H; Lu H; Ma NN; Hou BB; Li W; Kong FX; Yu JT; Hou R; Jin J; Wen JG; Zhang T; Meng XM Clin Transl Med; 2023 Aug; 13(8):e1359. PubMed ID: 37537731 [TBL] [Abstract][Full Text] [Related]
6. METTL3 potentiates progression of cervical cancer by suppressing ER stress via regulating m6A modification of TXNDC5 mRNA. Du QY; Huo FC; Du WQ; Sun XL; Jiang X; Zhang LS; Pei DS Oncogene; 2022 Sep; 41(39):4420-4432. PubMed ID: 35987795 [TBL] [Abstract][Full Text] [Related]
7. METTL3 facilitates prostate cancer progression via inducing HOXC6 m6A modification and stabilizing its expression through IGF2BP2-dependent mechanisms. He P; Liu X; Yu G; Wang Y; Wang S; Liu J; An Y Mol Cell Biochem; 2024 Jul; 479(7):1707-1720. PubMed ID: 38822192 [TBL] [Abstract][Full Text] [Related]
8. METTL3 suppresses invasion of lung cancer via SH3BP5 m6A modification. Zhang B; Qian R; Li X Arch Biochem Biophys; 2024 Feb; 752():109876. PubMed ID: 38141906 [TBL] [Abstract][Full Text] [Related]
9. RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner. Yu D; Pan M; Li Y; Lu T; Wang Z; Liu C; Hu G J Exp Clin Cancer Res; 2022 Jan; 41(1):6. PubMed ID: 34980207 [TBL] [Abstract][Full Text] [Related]
10. METTL3/IGF2BP2 axis affects the progression of colorectal cancer by regulating m6A modification of STAG3. Yi J; Peng F; Zhao J; Gong X Sci Rep; 2023 Oct; 13(1):17292. PubMed ID: 37828232 [TBL] [Abstract][Full Text] [Related]
11. Methyltransferase-like 3 induces the development of cervical cancer by enhancing insulin-like growth factor 2 mRNA-binding proteins 3-mediated apoptotic chromatin condensation inducer 1 mRNA stability. Su C; Zhang Y; Chen P; Yang W; Du J; Zhang D Bioengineered; 2022 Mar; 13(3):7034-7048. PubMed ID: 35255776 [TBL] [Abstract][Full Text] [Related]
12. Anti-HIV Drug Elvitegravir Suppresses Cancer Metastasis via Increased Proteasomal Degradation of m6A Methyltransferase METTL3. Liao L; He Y; Li SJ; Zhang GG; Yu W; Yang J; Huang ZJ; Zheng CC; He QY; Li Y; Li B Cancer Res; 2022 Jul; 82(13):2444-2457. PubMed ID: 35507004 [TBL] [Abstract][Full Text] [Related]
13. METTL3-regulated m6A modification impairs the decidualization of endometrial stromal cells by regulating YTHDF2-mediated degradation of FOXO1 mRNA in endometriosis-related infertility. Li X; Jin J; Long X; Weng R; Xiong W; Liang J; Liu J; Sun J; Cai X; Zhang L; Liu Y Reprod Biol Endocrinol; 2023 Oct; 21(1):99. PubMed ID: 37891533 [TBL] [Abstract][Full Text] [Related]
14. JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA. Ni Z; Sun P; Zheng J; Wu M; Yang C; Cheng M; Yin M; Cui C; Wang G; Yuan L; Gao Q; Li Y Cancer Res; 2022 May; 82(9):1789-1802. PubMed ID: 35502544 [TBL] [Abstract][Full Text] [Related]
15. SRSF9 promotes colorectal cancer progression via stabilizing DSN1 mRNA in an m6A-related manner. Wang X; Lu X; Wang P; Chen Q; Xiong L; Tang M; Hong C; Lin X; Shi K; Liang L; Lin J J Transl Med; 2022 May; 20(1):198. PubMed ID: 35509101 [TBL] [Abstract][Full Text] [Related]
16. Reduced N6-Methyladenosine Mediated by METTL3 Acetylation Promotes MTF1 Expression and Hepatocellular Carcinoma Cell Growth. Yang Y; Qian Cai Q; Sheng Fu L; Wei Dong Y; Fan F; Zhong Wu X Chem Biodivers; 2022 Nov; 19(11):e202200333. PubMed ID: 36149370 [TBL] [Abstract][Full Text] [Related]
17. N6-methyladenosine methyltransferase METTL3 promotes colorectal cancer cell proliferation through enhancing MYC expression. Xiang S; Liang X; Yin S; Liu J; Xiang Z Am J Transl Res; 2020; 12(5):1789-1806. PubMed ID: 32509177 [TBL] [Abstract][Full Text] [Related]
18. Cross talk between RNA N6-methyladenosine methyltransferase-like 3 and miR-186 regulates hepatoblastoma progression through Wnt/β-catenin signalling pathway. Cui X; Wang Z; Li J; Zhu J; Ren Z; Zhang D; Zhao W; Fan Y; Zhang D; Sun R Cell Prolif; 2020 Mar; 53(3):e12768. PubMed ID: 31967701 [TBL] [Abstract][Full Text] [Related]
19. METTL3-Mediated N6-Methyladenosine Methylation Modifies Foxp3 mRNA Levels and Affects the Treg Cells Proportion in Peripheral Blood of Patients with Asthma. Fan L; Wu J; Wang H; Chen Q; He X; Wang Q; Yang Z Ann Clin Lab Sci; 2022 Nov; 52(6):884-894. PubMed ID: 36564065 [TBL] [Abstract][Full Text] [Related]
20. METTL3 facilitates tumor progression via an m Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]